VANCOUVER, British Columbia, Jan. 16, 2017 /PRNewswire/ Lifestyle Delivery Systems Inc. (CSE: LDS), (OTCQB: LDSYF), and Borse Frankfurt Exchange (XETR: LD6) ( LDS or the Company ) is pleased to announce that it has begun outlining the protocols for clinical trails of its patent pending CannaStrips formula. LDS Chief Medical Officer, John Sanderson MD, having over 30 years of clinical research, clinical trial coordination and analysis experience, will oversee the protocols and operational aspects of the trials. The trials will be conducted
http://bit.ly/2jCwgYY
No comments:
Post a Comment